Midodrine for the Treatment of Refractory Hypotension

• Status: Completed
• Trial end date: 2019-06-01
• Target enrollment: 0
• Participant gender: All

Summary

We hypothesize that midodrine treatment of refractory hypotension in patients otherwise ready for discharge from the ICU shortens duration of receiving IV vasopressors and SICU length of stay without increasing MGH length of stay or putting the patient at risk of being readmitted to an ICU.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: Sir Charles Gairdner Hospital
• Treatments: Midodrine

Criteria

Inclusion Criteria:

• At least 18 years of age

• Admitted to the SICU

• Requiring IV vasopressors at a rate of less than 100 mcg/min of phenylephrine, or 8 mcg/min of norepinephrine, or 60 mcg/min of metaraminol; and unable to wean for more than 24 hours while still maintaining desired blood pressure goal

Exclusion Criteria:

• Inadequate tissue oxygenation

• Liver failure

• Renal failure

• Hypovolemic shock or hypotension due to adrenal insufficiency

• Pregnancy

• Severe organic heart disease

• Urinary retention

• Pheochromocytoma

• Thyrotoxicosis

• Midodrine as pre-admission medication

• Any known allergies to midodrine

• Enrollment in another clinical trial